Quick answer
Zurich Biotech ships lyophilized research peptides to Makassar and the wider South Sulawesi region, typically within one to two business days. Makassar is eastern Indonesia's main port and logistics gateway, so shipments route through the city before continuing to smaller Sulawesi centers such as Palopo, Parepare, and Kendari. BPOM Regulation No. 27 of 2022 (as amended by Regulation No. 8 of 2024) governs research-use imports of unregistered pharmaceuticals through the Special Access Scheme, and that framework applies in Makassar the same way it applies anywhere else in Indonesia.
BPOM and the regulatory framework for research imports
BPOM (Badan Pengawas Obat dan Makanan) is Indonesia's national drug and food regulator. Any pharmaceutical product without a domestic Marketing Authorization enters the country through a licensed channel. For research purposes, that channel is the Special Access Scheme (SAS), which covers research, clinical development, and other non-commercial scientific uses.
Research peptides are not classified as narcotics or psychotropics under Indonesian law, so they move through the standard SAS route. BPOM Regulation No. 8 of 2024, issued alongside Government Regulation No. 28 of 2024 implementing Law No. 17 of 2023 on Health, added a digital processing track that shortened turnaround time on SAS authorizations nationwide, including for shipments destined for eastern Indonesia.
For a researcher receiving an order in Makassar, the SAS authorization sits with the importing entity, not the individual recipient. Orders ship with a Certificate of Analysis; the COA guide covers what to check against the batch on arrival.
Shipping to Makassar and South Sulawesi
The Port of Makassar handles roughly 700,000 TEUs a year and functions as the primary distribution point for eastern Indonesia, the same role Surabaya plays for the central islands. Most domestic pharmaceutical cargo bound for Sulawesi, Maluku, or Papua now clears through Makassar rather than transiting Jakarta first, which cuts a leg off the cold-chain route compared to a few years ago.
South Sulawesi's existing cold-storage capacity was built for the tuna and skipjack export trade, not pharmaceuticals, but the infrastructure overlaps. PT Bonecom, one of the older frozen-seafood processors in the city, runs port-side freezing down to -25 degrees C with a rated cold-storage capacity of 14,700 tons a year. That kind of deep-freeze capacity sits well below what a lyophilized peptide shipment needs, so cold-chain couriers operating out of Makassar have margin to spare on temperature control during transit.
Same-day or next-day delivery covers the city proper: Panakkukang, Tamalanrea, Mariso, and the Losari waterfront district. Orders to Gowa, Maros, and Takalar in the immediate metro area arrive within one to two business days. Shipments continuing on to Parepare, Palopo, or across to Kendari in Southeast Sulawesi typically add a day or two, since they ride the same courier network rather than a dedicated line.
Climate and storage requirements in Makassar
Makassar sits in ICH Climatic Zone IVb, the hot-and-very-humid classification that sets accelerated pharmaceutical stability testing at 30 degrees C and 75% relative humidity. The city's own averages run close to that benchmark: about 27 degrees C year-round, with relative humidity between 75% and 89% depending on the month. Rainfall is heaviest from November through April, driven by the northwest monsoon, and lightest from June through September.
Lyophilized peptide picks up ambient moisture once a vial is opened to air under these conditions. A 2015 stability study on a lyophilized peptide hormone formulation, published in the International Journal of Pharmaceutics (Srinivasan et al., Int J Pharm 2015), recorded a 20 to 27% drop in peptide concentration after 8 weeks at 25 degrees C and 60% relative humidity, along with visible particulate formation in the reconstituted material. Makassar's ambient humidity runs above that test condition for most of the year.
Vials should go into a freezer at -20 degrees C or colder as soon as they arrive. A multi-site consensus on peptide handling for mass-spectrometry assays, published in Clinical Chemistry (Hoofnagle et al., Clin Chem 2016), recommends storage between -20 and -80 degrees C for anything held longer than six months. The same paper tested peptide samples through up to 10 freeze-thaw cycles and found no statistically significant drop in peak area compared to continuously refrigerated controls, though the authors still advise minimizing freeze-thaw events as routine practice rather than relying on that tolerance. A standard lab or household freezer set to -18 degrees C or below covers most research timelines of six to twelve months.
Reconstituted peptide belongs in the refrigerator at 2 to 8 degrees C between uses, not on a bench at room temperature. Grid power in central Makassar is stable; outer Gowa and Maros districts see more frequent short outages, so a small UPS on the storage freezer is worth the cost. Full guidance on freeze-thaw limits and desiccant use is in the article on lyophilized peptide storage in tropical climates.
Research environment in Makassar
Universitas Hasanuddin (UNHAS) is South Sulawesi's largest research university and the anchor institution for pharmaceutical science in eastern Indonesia. Its Faculty of Pharmacy carries 16 researchers and 734 recorded research outputs, including 563 journal articles, with rat pharmacology and toxicology work forming the largest single share of that output. The faculty also runs analytical work in transdermal drug delivery and anti-infective compounds, using in-house equipment that includes atomic absorption spectrophotometers and infrared spectrophotometers for quality-control analysis.
RSUP Dr. Wahidin Sudirohusodo, the national referral hospital in Makassar's Tamalanrea district, is affiliated with UNHAS's Faculty of Medicine and serves as one of eastern Indonesia's clinical trial sites in multi-center studies. It is one of seven hospital sites nationwide, alongside Jakarta, Surabaya, Medan, Denpasar, Semarang, and Yogyakarta, in the INA-RESPOND tuberculosis drug-resistance cohort study, a joint program between Indonesia's National Institute of Health Research and Development and the U.S. National Institute of Allergy and Infectious Diseases. That combination, a research-active pharmacy faculty plus a hospital enrolled in a national multi-site trial network, gives Makassar research infrastructure that most other eastern Indonesian cities do not have.
Research peptides ordered in Makassar
Orders from Makassar skew toward tissue-repair and metabolic compounds, similar to the pattern seen in Jakarta and Surabaya. BPC-157 and TB-500 account for the largest share, reflecting both university lab work and private wellness clinics running investigational protocols. GHK-Cu and MOTS-c orders come mostly from independent researchers rather than clinics, a split that differs from the more clinic-heavy demand seen in Jakarta's CBD corridor.
Retatrutide order volume has grown faster than any other compound over the past year, in line with the national trend as more researchers track the Phase 3 data on the triple GLP-1/GIP/glucagon agonist. For reconstitution and dosing math on any compound shipped to Makassar, the peptide dosing calculator handles the volume and concentration calculations for standard vial sizes and U-100 syringes.